Leo Wealth LLC increased its stake in Bristol Myers Squibb Company (NYSE: BMY) by 36.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,134 shares of the biopharmaceutical company's stock after acquiring an additional 14,033 shares

Savvy Advisors Inc. raised its holdings in shares of Bristol Myers Squibb Company (NYSE: BMY) by 20.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 57,170 shares of the biopharmaceutical company's stock after purchasing an additional 9,893 shares during the period. Savvy Advisors Inc.'s holdings

Perpetual Ltd raised its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 121.2% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,741 shares of the biopharmaceutical company's stock after buying an additional 36,562 shares during the

Element Squared LLC bought a new position in Bristol Myers Squibb Company (NYSE: BMY) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 48,420 shares of the biopharmaceutical company's stock, valued at approximately $2,612,000. Bristol Myers Squibb makes up approximately

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Bristol Myers Squibb Company (NYSE: BMY - Get Free Report) EVP David Elkins sold 30,000 shares of the firm's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248

BridgePort Financial Solutions LLC grew its stake in Bristol Myers Squibb Company (NYSE: BMY) by 228.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,021 shares of the biopharmaceutical company's stock after buying an additional 11,143 shares during the period. BridgePort

Compagnie Lombard Odier SCmA reduced its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 99.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,000 shares of the biopharmaceutical company's stock after selling 238,000 shares

JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform.

U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in exchange for three-year exemptions from tariffs on drug imports.